AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. Through relentless innovation and a commitment to scientific discovery we are catalysing changes in the practice of medicine to transform the patient experience. By working with the community, we can empower patients and caregivers, and are able to evolve the way cancer is treated by accelerating the uptake of the latest advancements.
Through collaborations with researchers, academia, healthcare providers, governments, industry and scientific organisations, patients and their families, we are uncovering unique insights on how we can establish new standards of screening, diagnostics and treatment.
I am passionate about developing medicines to improve the outcomes for patients with cancer and developing the skills and experience of the people within my team.
In the spotlight
New Normal, Same Cancer
To address the impact of the COVID-19 pandemic on cancer care worldwide, AstraZeneca has partnered with global patient coalitions representing millions of patients from around the world to launch New Normal, Same Cancer. This program raises awareness of the impact of COVID-19 and calls for patients to contact their doctor and return to cancer care services, including anyone who has paused treatment, missed routine checks or is experiencing symptoms that may be due to cancer
We have partnered with leading solution providers, scientific societies and clinical experts to create HAYA (pronounced hah-yah) - a fully-integrated cancer care management platform for patients, healthcare providers and care centres.
HAYA addresses the need for simplification of the oncology patient pathway by enabling continuity of care and connectivity between healthcare professionals and patients.
This unique platform combines telemonitoring, teleconsultation, home care services, treatment navigation, personalised support, tracking, motivation and education – all through a single interface. HAYA provides a holistic and personalised view of care plans from diagnosis to treatment to follow up
Lung Ambition Alliance
Lung cancer is at the forefront of AstraZeneca’s research and development focus. Our expanding portfolio aims to provide medicines that can improve outcomes at every stage of the disease. But we know if we are to make meaningful progress for lung cancer patients, we cannot work alone. We have partnered with the International Association for the Study of Lung Cancer (IASLC), the Global Lung Cancer Coalition (GLCC), and Guardant Health to form the Lung Ambition Alliance. Together we are taking urgent action to double five-year survival in lung cancer globally by 2025 – prioritising research and projects that increase screening, deliver innovative medicine and improve quality care
Patients as people first
Our commitment to patients
Our longstanding commitment to patients has led us to reimagine our patient-focused ways of working, as we embed it across every aspect of our company to deliver the healthcare experience and outcomes people care about most so they can enjoy fulfilling lives
Explore our Oncology pillars
Veeva ID: Z4-34100
Date of Prep: June 2021